Reports indicate that GeneDx Holdings Corp.'s Class A Common Stock saw notable insider accumulation during mid-May 2026. Director Keith A. Meister, who is also a ten percent owner of the firm, participated in these transactions alongside Corvex Management LP, which maintains a similar ten percent ownership stake. Together, they acquired a total value of $13,765,344 worth of the company's common stock.
These buying activities took place across three days, specifically between May 13 and May 15, 2026. The purchase prices for these shares ranged from a low of $38.28 to a high of $39.92 per share.
Detailed Breakdown of Acquisitions
The buying pattern was structured across multiple transactions:
- On May 13, 2026, Corvex Management LP executed two separate acquisitions. The first involved acquiring 94,074 shares at a weighted average price of $38.82 per share, with individual trade prices varying between $38.21 and $39.20. Following this, an additional purchase acquired 70,926 shares, which had a weighted average cost of $39.45, based on individual transaction prices ranging from $39.21 to $39.80.
- The following day, May 14, 2026, saw further buying activity. This included the purchase of 88,107 shares at a weighted average price of $39.08 per share, with individual prices observed between $38.79 and $39.77. Separately, 51,893 shares were acquired at a weighted average price of $39.92, reflecting individual trade prices that fell within the range of $39.79 to $40.00.
- The final reported buying day was May 15, 2026. On this date, Corvex Management LP purchased 27,408 shares at a weighted average price of $38.28, with transaction prices ranging from $37.78 to $38.77. Concluding the reported period, a final block purchase acquired 18,865 shares, priced at a weighted average of $39.83 per share, based on individual prices between $39.78 and $40.60.
Ownership Structures and Holdings
The financial holdings related to these transactions involve several key entities. Investment funds managed by Corvex Management LP are recorded as the direct holders of 4,784,570 shares of GeneDx Holdings Corp.'s Class A Common Stock. It is noted that Mr. Meister may be considered to indirectly benefit from these shares due to his control over the general partner of Corvex.
Both Corvex and Mr. Meister have formally stated that they disclaim beneficial ownership of the reported securities, except for the portion related to their direct pecuniary interest.
Furthermore, CMLS Holdings LLC is documented as the record holder of 333,144 shares of Class A Common Stock. Since Mr. Meister is one of two members serving on the Board of Managers of CMLS Holdings, he shares both voting rights and investment discretion over these specific securities.
In addition to his advisory role at Corvex, Mr. Meister directly holds 20,129 shares of Class A Common Stock. These personal holdings were issued following the vesting of restricted stock units that were granted in connection with his service on the company's board of directors.
Contextualizing Recent Corporate Performance
The reported insider purchases occurred amid recent financial disclosures by GeneDx Holdings Corp. The company recently released its first-quarter earnings report for 2026, which failed to meet analyst expectations. Specifically, the company announced an earnings per share (EPS) of -$0.28. This figure was lower than the projected EPS of -$0.01.
Revenue figures also fell short of estimates, reaching $102.3 million when analysts had anticipated $112.45 million. Following these disclosures, two major financial institutions adjusted their price targets for GeneDx. Canaccord reduced its price target from an earlier mark of $100 down to $75, while simultaneously maintaining a Buy rating, citing a softer overall revenue outlook. Similarly, BTIG lowered its price target from $170 to $90, also upholding a Buy rating after the company adjusted both its 2026 revenue and volume guidance downward.
The firm attributed this reduced forward-looking guidance primarily to an increased mix of genome tests. These types of tests currently possess less established reimbursement coverage when compared to exome tests. Despite the disappointing earnings report, the stock experienced a minor uptick in premarket trading, suggesting that some investors maintain confidence regarding GeneDx's strategic direction.